Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Intellia Therapeutics, Inc. Banner

Intellia Therapeutics, Inc.

NTLA Stock Analysis

Page title

Section title

About Intellia Therapeutics, Inc.

Biotechnology
Healthcare

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system...

Intellia Therapeutics, Inc. Key Metrics

Market Cap
$1B
52 Weeks Low
$12.82
52 Weeks High
$34.87
P/B
1.50x
P/E
-2.76x
P/S
33.76x

Upcoming Events

    NTLA Analyst Forecasts

    ‌
    ‌

    NTLA Financials

    NTLA Income Statement Key Metrics

    • Revenue(TTM)43.09 M
    • Gross Profit(TTM)35.51 M
    • EBITDA(TTM)-527.52 M
    • Net Income(TTM)-522.28 M
    • EPS Diluted(TTM)-5.44

    Decode NTLA's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    NTLA earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of NTLA (0.753) is higher than the average of its peers (0.610).

    Net Profit Margin vs Peers

    Net profit margin ratio of NTLA (-13.265) is lower than the average of its peers (-2.842).

    NTLA Return on Equity

    See how efficiently NTLA generates profit for it's shareholders.

    -45.82%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of NTLA (-0.458) is higher than the average of its peers (-0.479).

    Return on Equity Growth

    NTLA's Return on Equity has shown poor growth over the past 10 years, increasing by only -13.22%.

    NTLA Revenue Growth

    See how NTLA has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    NTLA's revenue has grown significantly over the past 10 years, increasing by over 0%.